临床实验室Real Diagnostics收购SimplyTest，通过基于唾液的口腔健康检测拓展其高复杂度实验室产品组合-动脉网

Real Diagnostics Acquires SimplyTest, Expands Its High-Complexity Laboratory Portfolio with Salivaased Oral Health Testing

CISION 等信源发布 2026-10-22 20:32



可切换为仅中文







Acquisition adds Periodontal health testing to Real Diagnostics' molecular diagnostic laboratory offering for dental providers.

此次收购为 Real Diagnostics 面向牙科服务提供商的分子诊断实验室服务增添了牙周健康检测项目。

REISTERSTOWN, Md.

马里兰州赖斯特敦

，

Oct. 22, 2026

2026年10月22日

/PRNewswire/ -- Real Diagnostics, a CLIA-certified clinical laboratory specializing in high-complexity molecular infectious disease and toxicology testing, today announced it has acquired SimplyTest

/PRNewswire/ -- 专注于高复杂度分子传染病和毒理学检测的CLIA认证临床实验室Real Diagnostics今日宣布收购SimplyTest

, a leading provider of saliva-based diagnostic tests for oral health. Terms of the transaction were not disclosed. Real Diagnostics is a portfolio company of HCAP Partners, a California-based private equity firm and nationally recognized impact investor.

，一家领先的基于唾液的口腔健康诊断测试提供商。交易条款未予披露。Real Diagnostics 是 HCAP Partners 旗下的投资组合公司，HCAP Partners 是一家总部位于加利福尼亚州的私募股权公司，也是全国公认的具有社会影响力的投资者。

继续阅读

SimplyTest PERIO

SimplyTest's flagship product PERIO, uses a proprietary non-invasive swish-and-spit saliva sample to identify key periodontal pathogens, providing clinicians organism-level data to personalize therapy and monitor patient periodontal health over time.

SimplyTest 的旗舰产品 PERIO 采用专有的无创漱吐唾液样本检测技术，用于识别关键牙周病原体，为临床医生提供菌种层面的数据，以实现个性化治疗并长期监测患者的牙周健康状况。

Real Diagnostics offers high-complexity PCR-based (molecular) testing in urinary tract and sexually transmitted infections, vaginosis, respiratory and toxicology. Real Diagnostics combines micro-lab capabilities and molecular testing to provide phenotypic antibiotic resistance analysis, giving medical providers key insights into patient and pathogen specific antibiotic treatment options that optimize patient outcomes and antibiotic stewardship objectives.

Real Diagnostics 提供基于聚合酶链反应（PCR）的高复杂度分子检测，涵盖泌尿道感染、性传播感染、阴道病、呼吸道感染及毒理学领域。Real Diagnostics 将微型实验室能力与分子检测相结合，提供表型抗生素耐药性分析，为医疗提供者提供关于针对患者和病原体的特定抗生素治疗方案的关键洞察，从而优化患者预后并促进抗生素管理目标的实现。

Adding the SimplyTest.

添加 SimplyTest。

PERIO product extends the Real Diagnostics portfolio into oral health and broadens the range of provider types Real Diagnostic will now serve, including dental practices.

PERIO产品将Real Diagnostics的产品组合扩展至口腔健康领域，并扩大了Real Diagnostics现在所服务的提供者类型范围，包括牙科诊所。

'We are thrilled to incorporate the visionary leadership and deeply talented team at SimplyTest, whose commitment to innovation has redefined industry standards and enhances our mission of humanizing healthcare,' said Cary Breese, CEO, Real Diagnostics. 'The natural affinity between our operations enables us to seamlessly integrate the SimplyTest.

“我们非常高兴能够将 SimplyTest 富有远见的领导层和才华横溢的团队纳入旗下，他们对创新的承诺重新定义了行业标准，并强化了我们使医疗保健更具人性化的使命。”Real Diagnostics 首席执行官 Cary Breese 表示。“我们业务之间的天然契合使我们能够无缝整合 SimplyTest。”

PERIO product into our best-in-class provider service model and begin immediately serving dental practices with the most advanced diagnostic tools available to improve patient health outcomes.'

将 PERIO 产品融入我们行业领先的提供商服务模式，并立即开始为牙科诊所提供服务，利用最先进的诊断工具改善患者的健康结果。

'The addition of molecular oral health testing complements Real Diagnostics' industry-leading high complexity PCR-testing expertise.' Said Ben Consoli, Vice President, HCAP Partners. 'We are proud of the team at Real Diagnostics, and this strategic acquisition aligns with Real Diagnostics' work to accelerate the delivery of next-generation diagnostic solutions to a broader range of providers and patients.'.

“分子口腔健康检测的加入，补充了Real Diagnostics在行业领先的高复杂度PCR检测方面的专业能力。”HCAP Partners副总裁Ben Consoli表示。“我们为Real Diagnostics的团队感到自豪，此次战略收购与Real Diagnostics致力于加速向更广泛的医疗服务提供者和患者交付下一代诊断解决方案的工作相契合。”

Benefits to Providers and Patients Now Served by Real Diagnostics:

Real Diagnostics 目前服务的提供商和患者所获得的益处：

Broader menu of testing:

更广泛的测试菜单：

Providers can access oral health testing through one laboratory relationship.

提供者可以通过一个实验室合作关系获取口腔健康检测服务。

Continuity of service:

服务连续性：

Simply Test's PERIO product and provider support will continue without interruption.

Simply Test 的 PERIO 产品及其供应商支持将持续不间断。

Laboratory quality:

实验室质量：

Testing will continue to be performed under CLIA-certified laboratory standards.

检测将继续按照CLIA认证的实验室标准进行。

SimplyTest provider clients can continue to contact support through the SimplyTest Provider Portal or via

SimplyTest 提供商客户可以继续使用 SimplyTest 提供商门户或通过

[email protected]

。

About Real Diagnostics

关于 Real Diagnostics

Real Diagnostics is a CLIA-certified,

Real Diagnostics 是一家获得 CLIA 认证的机构，

high-complexity clinical laboratory

高复杂度临床实验室

specializing in advanced molecular biology, microbiology, and toxicology services. Utilizing state-of-the-art Polymerase Chain Reaction (PCR) technology, the firm's high efficiency lab operations deliver rapid diagnostic results that provide clinicians with state-of-the art diagnostics to promote better patient health outcomes and support effective antimicrobial stewardship.

专注于提供先进的分子生物学、微生物学和毒理学服务。公司利用最先进的聚合酶链式反应（PCR）技术，通过高效的实验室运营提供快速诊断结果，为临床医生提供前沿的诊断手段，从而改善患者健康结局，并支持有效的抗菌药物管理。

Real Diagnostics is deeply committed to best-in-class medical provider service, partnering with hundreds of hospitals, doctors, and medical offices nationwide to provide seamless billing, clear reporting, and an integrated, secure results portal. For more information, visit .

Real Diagnostics 致力于提供一流的医疗服务提供商支持，与全国数百家医院、医生及医疗机构合作，提供无缝账单处理、清晰的报告以及集成且安全的结果门户。欲了解更多信息，请访问。

www.realdxlabs.com

。

About HCAP Partners

关于 HCAP Partners

HCAP Partners is a private equity firm specializing in providing mezzanine debt and private equity for underserved, lower-middle market companies throughout the United States. The firm seeks to invest $5 million to $35 million in established businesses generating between $10 million and $100 million in revenues in the healthcare, software, services, and manufacturing industries.

HCAP Partners 是一家私募股权公司，专注于为全美服务不足的中低端市场企业提供夹层债务和私募股权投资。该公司寻求向营收介于1,000万美元至1亿美元之间的成熟企业投资500万至3,500万美元，这些企业主要分布在医疗保健、软件、服务和制造业领域。

Since its founding, HCAP Partners has invested in over 65 companies and, through active engagement with portfolio companies, provides value-added resources to help optimize performance and increase enterprise value. The firm has a strong history as an impact fund, recognized as an ImpactAssets 50 fund every year since 2014, and is a founding member of both the Global Impact Investing Network and Impact Capital Managers.

自成立以来，HCAP Partners 已投资超过65家公司，并通过与投资组合公司的积极互动，提供增值资源，以帮助优化绩效并提升企业价值。作为一家具有深厚积淀的影响力投资基金，该公司自2014年以来每年均被认定为“ImpactAssets 50”基金，并且是全球影响力投资网络（GIIN）和影响力资本管理者协会（Impact Capital Managers）的创始成员。

Through its Gainful Jobs Approach™, HCAP Partners works to facilitate a positive impact on underserved businesses, their employees, and their communities. For more information, please visit .

通过其“增益就业途径™”，HCAP Partners 致力于对服务不足的企业、其员工及其社区产生积极影响。如需更多信息，请访问。

www.hcap.com

。

Media Contact:

媒体联系人：

Jarrod Rudo

贾罗德·鲁多

Chief Operating Officer

首席运营官

410-833-3025

[email protected]

SOURCE Real Diagnostics, LLC